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Abstract 
Three different tetraazamacrocyclic ligands containing four amide substituents that feature 
groups (namely allyl, styryl and propargyl groups) suitable for polymerisation have been 
synthesised. Gadolinium(III) complexes of these three ligands have been prepared as 
potential monomers for the synthesis of polymeric MRI contrast agents. To assess the 
potential of these monomers as MRI contrast agents, their relaxation enhancement properties 
and cytotoxicity have been determined. A europium(III) complex of one of these ligands 
(with propargyl substituents) is also presented together with its PARACEST properties. In 
addition, to gain further insight into the coordination chemistry of the tetra-propargyl 
substitited ligand, the corresponding zinc(II) and cadmium(II) complexes have been prepared. 
The X-ray crystal structures of the tetra-propargyl ligand and its corresponding 
gadolinium(III), zinc(II) and cadmium(II) complexes are also presented. 
Introduction 
Polyazamacrocycles substituted with coordinating pendant arms have shown to be excellent 
ligands for a wide range of metal ions.
1,2
 The resulting complexes are generally 
thermodynamically very stable, which has resulted in these systems being used in a range of 
different applications.
3
 For example, coordination of this type of ligand to metals such as 
90
Y, 
68
Ga and 
111
In yields complexes that have been successfully used as radiopharmaceuticals for 
imaging and therapy.
4-10
 On the other hand, complexes of substituted polyazamacrocycles 
with lanthanides (e.g. Eu
III
, Tb
III
 and Gd
III
) have been shown to be excellent molecular probes 
for optical
11-15
 and magnetic resonance imaging (MRI).
16-19
  
There are currently five gadolinium(III) complexes approved by the FDA for use as 
MRI contrast agents in the US. From these, two (Dotarem® and Prohance®) are based on 
tetraazamacrocyclic derivatives (see Scheme 1). In spite of the great impact these complexes 
have had in the medical applications of MRI, their performance at clinically relevant 
concentrations is limited and well below what can be achieved theoretically.
20
 Consequently, 
there has been interest in finding new types of complexes that optimise the various factors 
which affect the ability of gadolinium(III) to change the relaxation time of water molecules.
21
 
Several approaches have been investigated such as increasing the number of water molecules 
coordinating to gadolinium (q); optimising the water exchange rate (1/τm); increasing the 
rotational correlation time (τR) of the contrast agent. The later is a promising approach and 
has been successfully employed by attaching gadolinium complexes to high molecular weight 
platforms such as cyclodextrins,
22,23
 dendrimers
24-28
 and less well defined polymers.
21,29,30
 
Besides their potential beneficial effect in slowing tumbling, high molecular weight materials 
also have the advantage of increasing the load of gadolinium per molecule with the 
consequent increase in relaxivity.
31
 Another interesting approach that has been gaining terrain 
recently is the development of lanthanide-based MRI contrast agents that operate via the 
chemical exchange saturation transfer (CEST) mechanism.
32-34
 These PARACEST agents are 
often based on Ln-DOTA-tetramide complexes (e.g. with Eu and Yb); this type of complex 
displays very slow water exchange kinetics which is ideal for the CEST phenomenon to take 
place. Also in this approach, there is interest in developing polymeric materials containing a 
large number of lanthanide centres to provide highly sensitive molecular probes.
35
    
 
For the reasons outlined above, we are interested in developing novel MRI contrast 
agents based on hyperbranched polymers. Therefore, we have synthesised a series of 
tetraazamacrocyclic ligands containing four amide substituents that feature functional groups 
suitable for free-radical, ADMET, cross-coupling and cycloaddition (e.g. 1,3-dipolar 
cycloadditions, “click”) polymerisation approaches (see Scheme 2).  
 
 
Scheme 1 –Two examples, Dotarem® and Prohance®, of clinically approved MRI contrast 
agents that make use of the azamacrocyclic ligands DOTA and HPDO3A shown in this 
scheme.  
 
 
Herein we present the synthesis and characterisation of three of such tetraazamacrocyclic 
ligands and their corresponding gadolinium(III) complexes (and in one case also a 
europium(III) complex). To assess their potential as MRI contrast agents (as part of a larger 
polymeric structure), their relaxation enhancement properties have been investigated as well 
as their cytotoxicity at concentrations relevant for MRI. As per the europium(III) complex 
herein presented, its potential as PARACEST agent has been evaluated. In addition, to gain 
insight into the structural features of the ligands and complexes, X-ray crystallographic 
studies have been carried out of one of the ligands (the tetra-propargyl derivative) and its 
corresponding gadolinium(III), cadmium(II) and zinc(II) complexes.  
 
Results and Discussion 
Synthesis 
The tetra-substituted tetraazamacrocyclic ligands 4-6 (see Scheme 2) were prepared by 
reacting cyclen with the corresponding chloro-acetamides (1-3). Compounds 4 and 6 have not 
been reported before while the synthesis of 5 (via a different route) was published by Antoni 
in the course of this investigation.
36
 The three products were isolated as white or off-white 
solids in 58 to 74% yields and were fully characterised by spectroscopic and analytical 
techniques, and in one case (compound 5) by X-ray crystallography (vide infra).   
The three cyclen derivatives were then reacted in water with GdCl3 to yield the new 
complexes 7, 8 and 10 (see Scheme 2). In each case, after 4 hours, the corresponding reaction 
mixture was analysed for free Gd
III
 using the Methyl Thymol Blue (MTB) test. In all cases 
the test was negative indicating that all the gadolinium(III) had coordinated to the 
corresponding ligand. The solvent was then removed under reduced pressure and the solid 
residue washed thoroughly with CH2Cl2 or THF (to remove any unreacted ligand) yielding 
the three gadolinium(III) complexes as white solids. ESI(+) mass spectrometry of these 
complexes showed molecular peaks at 716, 708 and 964 a.m.u. for 7, 8 and 10 respectively 
consistent with the formula [Gd+L–2H]+ (where L = 4, 5 or 6). The formulation of the 
complexes was confirmed by elemental analyses. In addition, one of the complexes (8) was 
structurally characterised by single crystal X-ray crystallography (vide infra) confirming the 
octa-coordination of the gadolinium(III) centre by the tetra-substituted cyclen ligand.  
 
 
 
 
Scheme 2 – Reaction scheme showing the syntheses of all ligands and metal complexes used 
in this study.  
The europium complex 9 (see Scheme 2) was prepared using a similar synthetic 
methodology than that used for to the gadolinium(III) complex 8 described above. Mass 
spectrometry, 
1
H NMR spectroscopy and elemental analyses were all consistent with the 
formation of the correct complex.
37
 Interestingly, in the region above 5 ppm (where the 
resonance for the axial ethylene unit appears) only one resonance at 24 ppm was observed. 
This resonance and the absence of any other between 5 and 12 ppm suggest that in solution 
complex 9 is present in a mono-capped square antiprismatic geometry and not as a mixture of 
isomers (the second being the mono-capped twisted square antiprismatic geometry ) as is 
often the case with DOTA-tetramide lanthanide complexes.
37
 In addition, the emission 
spectrum of this complex was recorded showing the expected transitions for cyclen-based 
europium(III) complexes
38
 (see Figure 1).  
 
 
Figure 1 – Emission spectrum of the Eu-tetraalkynyl complex 9 excited at 345 nm. The 
spectrum shows the characteristic 
5
D0 →
7
FJ transtions (ΔJ = 0, 1, 2, 3, 4) for europium(III) 
complexes coordinated to cycle-based ligands. 
 
 
In order to gain more insight into the coordinating abilities of these ligands, one of them 
(ligand 5) was also reacted with zinc(II) and cadmium(II) perchlorates. It has been previously 
shown that these metal ions (in particular cadmium(II)) often coordinate to cyclen derivatives 
in a similar fashion than gadolinium(III) does.
39
 An advantage of using cadmium(II) and 
zinc(II) is that, having a closed shell (d
10
), they are diamagnetic and therefore the resulting 
complexes can be studied by NMR spectroscopy. Thus, reaction of the tetra-propargyl ligand 
with Cd(ClO4)2 and Zn(ClO4)2∙6H2O yielded complexes 11 and 12 respectively (see Scheme 
2). Both complexes were obtained as white solids and characterised by spectroscopic, 
analytical and structural techniques. The 
1
H NMR spectrum of cadmium complex 11 is 
generally broader as compared to that of the free ligand. The protons of cyclen are slightly 
more shielded and appear as a broad signal centred at 2.45 ppm (cf. a singlet at 2.62 ppm for 
the free ligand). The alkyne protons appear at 3.20 ppm as opposed to 3.05 ppm in the free 
ligand, while the amide protons appear downfield at 9.17 ppm (cf. 8.42 ppm in the free 
ligand). Upon coordination of zinc(II) to ligand 5, the CH2 protons of cyclen become 
unequivalent and two different signals (at 2.67 and 3.02, c.f. one signal at 2.61 for the free 
ligand)  can be observed. The mass spectra of both these complexes showed peaks at 715 and 
765 a.m.u. which correspond to [M(5)ClO4]
+
 (M = Cd, Zn). 
 
X-ray crystal structures of compounds 5, 8, 11 and 12. The structures of the tetra-
propargyl cyclen ligand (5), and its complexes with gadolinium (8), cadmium (11) and zinc 
(12) are shown in Figures 2 – 5; selected bond lengths and angles for the complexes are given 
in Tables 1, 2 and 3. It can readily be seen that whilst in the free ligand the four amide arms 
are spread out (Figure 2), in the presence of a metal ion coordinated to all four of the cyclen 
nitrogen centres, some or all of the arms wrap around and encapsulate the metal centre.  
 
(b) 
 
 
 
 
(a) 
 
 
 
 
Figure 2 The structure of the Ci-symmetric molecule 5. 
 
In the gadolinium and cadmium complexes 8 and 11, the tetra-propargyl cyclen ligand 
adopts an octadentate coordination mode with the carbonyl oxygen atoms of all four amide 
arms binding to the metal (see Figure 3 and 4).  
                    
Fig. 3 (a) The molecular structure of the cation present in the crystals of 8; (b) The 
coordination sphere around the gadolinium atom in the structure of 8 showing the 
mono-capped Archimedean anti-prismatic coordination geometry. 
 
 
 
In the zinc complex 12 however, the ligand adopts a hexadentate coordination mode with 
only two of the amide arms (a pair opposite each other) linking to the metal (see Figures 5 
and 6). The additional coordination of a water molecule [O(40)] in the gadolinium complex 8 
(a) 
 
(b) 
 
 
 
 
gives rise to a mono-capped Archimidean antiprismatic coordination geometry with O(40) in 
the capping position. The cadmium complex 11 has a coordination geometry intermediate 
between cubic and Archimidean antiprismatic, whilst the zinc complex 12 has an octahedral 
coordination geometry. 
 
 
 
 
 
Fig. 4 (a) The molecular structure of the C2-symmetric cationic complex present in the 
crystals of 11, viewed along the crystallographic C2 axis direction. (b) The 
coordination sphere around the cadmium atom in the structure of 11 showing the 
“intermediate between cubic and Archimedean anti-prismatic” coordination geometry. 
 
The change in conformation of the ligand arms between the free ligand and the three 
metal complexes is reflected in the X–N–C–C [where X is either the nitrogen lone pair (5)40 
or the coordinated metal atom (8, 11 and 12)] and N–C–C–O torsion angles for each of the 
amide arms (Tables 4 and 5). For one of the nitrogen atoms of the macrocycle and its 
associated amide oxygen atom to bind to the same metal their X–N–C–C and N–C–C–O 
torsion angles must both be small so that the nitrogen lone pair or bonding pair and the 
oxygen atom point in approximately the same direction. The chelating arms in complexes 8 
and 11 all have X–N–C–C torsion angles with magnitudes in the range 35 – 43°, and N–C–
C–O torsion angles with magnitudes in the range 23 – 36° (the deviations from zero being 
due to the preferential coordination geometries of the particular metal atom). In the ligand 5, 
the N(1)-based amide arm has X–N–C–C and N–C–C–O torsion angles of 25 and –167° 
respectively, showing that the O(14) oxygen atom is in the wrong position relative to N(1) for 
chelation. For the N(4)-based arm, by contrast, the X–N–C–C and N–C–C–O torsion angles 
of –45 and –5° respectively show that this unit is ideally arranged for chelation. However, 
significant rearrangement would still be required for both this unit and its 
centrosymmetrically related counterpart to chelate to the same metal as they are currently on 
opposites sides of the tetraaza macrocycle. The zinc complex 12 has two coordinated arms 
and two non-coordinated arms. For the coordinated arms the X–N–C–C and N–C–C–O 
torsion angles are 15 and –21° respectively, whilst for the non-coordinated arms they are ca. 
168 and 43° respectively. 
 
 
 
Fig. 5 The molecular structure of the C2-symmetric cationic complex present in the crystals 
of 12, viewed along the crystallographic C2 axis direction. 
 
 
 
 
 
Fig. 6 The coordination sphere around the zinc atom in the structure of 12 showing the 
distorted octahedral coordination geometry. 
 
 
Table 1. Selected bond lengths (Å) and angles (°) for 8. 
Gd–N(1) 2.652(4)  Gd–N(4) 2.664(4) 
Gd–N(7) 2.677(4)  Gd–N(10) 2.623(4) 
Gd–O(14) 2.387(3)  Gd–O(20) 2.393(3) 
Gd–O(26) 2.363(3)  Gd–O(32) 2.424(3) 
Gd–O(40) 2.437(3)    
     
N(1)–Gd–N(4) 68.12(12)  N(1)–Gd–N(7) 104.86(12) 
N(1)–Gd–N(10) 68.85(12)  N(1)–Gd–O(14) 66.20(12) 
N(1)–Gd–O(20) 71.99(12)  N(1)–Gd–O(26) 141.67(12) 
N(1)–Gd–O(32) 132.78(12)  N(1)–Gd–O(40) 126.53(12) 
N(4)–Gd–N(7) 67.65(12)  N(4)–Gd–N(10) 105.11(13) 
N(4)–Gd–O(14) 130.77(12)  N(4)–Gd–O(20) 65.76(12) 
N(4)–Gd–O(26) 74.35(12)  N(4)–Gd–O(32) 139.60(12) 
N(4)–Gd–O(40) 126.76(12)  N(7)–Gd–N(10) 68.34(13) 
N(7)–Gd–O(14) 142.18(12)  N(7)–Gd–O(20) 130.57(12) 
N(7)–Gd–O(26) 66.26(12)  N(7)–Gd–O(32) 72.93(11) 
N(7)–Gd–O(40) 128.59(12)  N(10)–Gd–O(14) 74.42(12) 
N(10)–Gd–O(20) 140.14(12)  N(10)–Gd–O(26) 130.66(12) 
N(10)–Gd–O(32) 66.82(11)  N(10)–Gd–O(40) 128.12(12) 
O(14)–Gd–O(20) 83.43(11)  O(14)–Gd–O(26) 143.27(11) 
O(14)–Gd–O(32) 86.80(11)  O(14)–Gd–O(40) 71.55(11) 
O(20)–Gd–O(26) 86.00(11)  O(20)–Gd–O(32) 145.29(11) 
O(20)–Gd–O(40) 72.04(11)  O(26)–Gd–O(32) 82.20(11) 
O(26)–Gd–O(40) 71.73(11)  O(32)–Gd–O(40) 73.27(11) 
 
 
 
 
 
 Table 2. Selected bond lengths (Å) and angles (°) for 11. 
Cd–N(1) 2.4762(15)  Cd–N(4) 2.4380(15) 
Cd–O(14) 2.3915(12)  Cd–O(20) 2.4024(12) 
     
N(1)–Cd–N(4) 74.45(6)  N(1)–Cd–O(14) 68.26(5) 
N(1)–Cd–O(20) 91.89(5)  N(1)–Cd–N(1A) 118.04(7) 
N(1)–Cd–N(4A) 74.42(5)  N(1)–Cd–O(14A) 160.53(5) 
N(1)–Cd–O(20A) 123.72(4)  N(4)–Cd–O(14) 124.44(4) 
N(4)–Cd–O(20) 69.35(5)  N(4)–Cd–N(4A) 117.17(7) 
N(4)–Cd–O(14A) 90.81(5)  N(4)–Cd–O(20A) 161.47(5) 
O(14)–Cd–O(20) 72.26(4)  O(14)–Cd–O(14A) 112.44(6) 
O(14)–Cd–O(20A) 70.70(4)  O(20)–Cd–O(20A) 110.33(6) 
 
 
Table 3. Selected bond lengths (Å) and angles (°) for 12. 
Zn–N(1) 2.231(2)  Zn–N(4) 2.182(2) 
Zn–O(14) 2.0920(15)    
     
N(1)–Zn–N(4) 82.08(9)  N(1)–Zn–O(14) 78.10(7) 
N(1)–Zn–N(1A) 126.08(12)  N(1)–Zn–N(4A) 79.75(7) 
N(1)–Zn–O(14A) 152.27(8)  N(4)–Zn–O(14) 92.09(7) 
N(4)–Zn–N(4A) 139.23(13)  N(4)–Zn–O(14A) 119.02(8) 
O(14)–Zn–O(14A) 83.03(8)    
 
 
Table 4. Comparative X–N–C–C torsion angles (°) for each amide arm of the tetra-
propargyl cyclen ligand in the structures of 5, 8, 11 and 12.
[a] 
 5 8 11 12 
X–N(1)–C–C 25 –35 –42 15 
X–N(4)–C–C –45 –40 –43 168 
X–N(7)–C–C n/a –37 n/a n/a 
X–N(10)–C–C n/a –38 n/a n/a 
[a]
 X is either the nitrogen lone pair or the coordinated metal atom.
40
 
 
 
 
Table 5. Comparative N–C–C–O torsion angles (°) for each amide arm of the tetra-
propargyl cyclen ligand in the structures of 5, 8, 11 and 12. 
 5 8 11 12 
N(1)–C–C–O(14) –167 23 30 –21 
N(4)–C–C–O(20) –5 36 30 43 
N(7)–C–C–O(26) n/a 30 n/a n/a 
N(10)–C–C–O(32) n/a 31 n/a n/a 
 
 
 
 
 
Determination of relaxivity of gadolinium complexes 7 and 8. Once the 
gadolinium complexes 7, 8 and 10 were prepared and fully characterised, it was of interest to 
determine their potential as MRI contrast agents. Therefore relaxivity determinations were 
carried out using two of the complexes (7 and 8). Complex 10 showed to have limited 
solubility in water and therefore was excluded of any further relaxivity and cell viability (see 
next section) studies. Relaxation rates were measured at 25°C using 2.35 T (100 MHz) and 
9.4 T (400 MHz) systems. Solutions of the corresponding complexes at 0.1–2.5 mM 
concentration range in double distilled water were prepared and the relaxivities determined 
(see Table 6).  
 
 
 
Table 6 Longitudinal (r1) and transversal (r2) relaxivities calculated for complexes 7 and 8 at different 
magnetic field strengths (B). 
Compound 
B =  2.35 T B = 9.4 T 
r1 (mM
-1
 s
-1
) r2 (mM
-1
 s
-1
) r1 (mM
-1
 s
-1
) r2 (mM
-1
 s
-1
) 
7 2.84 3.74 2.25 3.41 
8 2.86 2.47    2.83    4.79 
 
 
The r1 values obtained for these compounds are comparable to other gadolinium(III) 
complexes with amide-functionalised DOTA ligands. For example, the relaxivities for Gd-
DOTAM,
41
 Gd-DOTTA
41
 and Gd-DOTA-benzyl-amide
42
 (measured at 0.47 T, 
corresponding to a proton Larmor frequency of 20 MHz) have been previously reported to be 
2.5, 3.0 and 1.88 mM
-1
 s
-1
 respectively. The transversal relaxivities (r2) of complexes 7 and 8 
were also determined by using a spin-echo technique. This parameter is rarely reported for 
Gd-based contrast agents and indeed no transversal relaxivity values were found in the 
literature for any Gd-DOTA-tetraamide complexes making any comparison difficult. As a 
reference, the previously reported r2 value (at B = 2.35 T) for Gd-DOTA is 4.9 mM
-1
 s
-1
.
43
  
 
CEST spectrum of PARACEST agent 9. The PARACEST spectrum of the europium 
complex 9 was recorded (see Figure 7) by applying selective saturation between +100 and –
100 ppm. The CEST profile of this complex is consistent with analogous DOTA-tetramide 
europium(III) complexes showing intermediate to slow water exchange between the Eu-
bound water species (ca. δ = 50 ppm) and that of bulk water (ca. δ = 0 ppm).37,44 
 
 
Figure 7. CEST spectrum of a 20 mM solution of europium(III) complex 9 at neutral pH 
(B0= 9.4 T, 294±1 K, irradiation time 2s, B1 = 22.1 µT). 
 
 
 
Cell viability studies of gadolinium complexes. The toxicity of complexes 7 and 8 
was investigated by incubating ST14A stem cells
45
 (an immortalized neural stem cell line 
derived from embryonic striatum at developmental stage E14) in solutions containing 
different concentrations of the corresponding complex, at 33°C and 5% CO2 atmosphere for 
24 hours. Solutions of 7 and 8 ranging from 0.01 to 10 mM were prepared in DMEM. 
Incubation was then carried out with these solutions, after which the cells were washed with 
EBSS and tested for viability. Cells were first checked under an inverted microscope to 
assess morphological changes as possible occurrence of cell death. Figure 8 shows examples 
of the morphology of cells after being exposed to different concentrations of the complex (in 
this case complex 7). Whereas 1 mM concentration of compound 7 does not overtly affect 
cell morphology as compared to controls (Figure 8A-B), most cells seem to be dying by 24 
hours in the presence of a 10 mM concentration of compound 7 (Figure 8C).  
 
 
 
 
 
 
 
 
 
Figure 8. Optical images of cells as seen under an inverted microscope after exposure to 
different concentrations of gadolinium(III) complex 7. A) Untreated control cells. B) Cells 
incubated with a 1 mM concentration of compound 7 displayed a similar morphology to the 
healthy untreated control cells (A). C) Cells treated with a 10 mM concentration of 
compound 7. Note the round morphology typical of dead or dying cells. 
 
A B C 
For a quantitative analysis of the effect of compounds 7 and 8 on cell survival, change 
in cell metabolism was assessed using the Alamar Blue (Figure 9 and Table 7)
46
 and 
Methylene Blue
47
 assays (Figure 10 and Table 7). These methods utilize dyes that detect 
either changes in the redox state of the culture medium resulting from cell growth (Alamar 
Blue assay), or that bind to living cell membranes (Methylene Blue assay). Across the range 
of concentrations, both complexes showed similar metabolic activity and cytotoxicity as the 
control cells which were not exposed to gadolinium complexes. In the Alamar Blue assay, a 
small, though statistically different, reduction in cell number appeared to be induced by 
treatment with compound 8 at 0.1 mM and 0.01 mM (Figure 7; p=0.015). In the Methylene 
Blue assay, a concentration-dependent effect on cell viability was observed, and cell number 
at 3 mM using compound 8 was statistically lower than in control cells (Figure 8; p=0.001). 
Microscopy indicated that cells at the range of concentrations tested in the viability assays 
(0.01-3 mM) were not visibly undergoing cell death, suggesting that the results of the Alamar 
Blue and Methylene Blue assays may reflect an effect of the compounds on cell metabolism 
and proliferation, respectively, rather than in cell survival. Whereas the Methylene Blue assay 
provides a measure of the dye bound to living cell membranes, and its binding is an indicator 
of the number of cells in culture,
47
 the Alamar Blue assay detects dye colour changes due to 
oxidation–reduction activity, providing a measure of cell metabolic activity. Altogether our 
results suggest that compound 7 is non-toxic at and below 3 mM, while at 3 mM cell numbers 
decrease for compound 8.  
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Figure 9. Effect of compounds 7 and 8 on cell viability assessed by Alamar Blue assay. 
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Figure 10. Effect of compounds 7 and 8 on cell viability assessed by Methylene Blue assay. 
 
Table 7 Summary of the effect (+ = positive; – = negative) on cell viability for Gd-
complexes 7 and 8. 
 
Compound Concentration (mM) 
0.01 0.1 0.5 1.0 2.0 3.0 10.0 
7 + + + + + + - 
8 + + + + + - - 
 
Conclusions 
Three tetra-amide substituted ligands and the corresponding gadolinium(III) complexes have 
been prepared. In one case (with ligand 5) the corresponding europium(III) complex has also 
been synthesised. These ligands were designed to feature readily polymerisable groups (i.e. 
terminal alkenes or alkynes) for their potential use as monomers in the synthesis of cyclen-
containing hyperbranched polymers. Two of the new gadolinium(III) complexes, were further 
studied to determine their relaxivities (r1 and r2) and cytotoxicity. Both these complexes show 
longitudinal relaxivities comparable to the values previously reported for other Gd
III
 
complexes with tetraamide-DOTA ligands. It should be noted that Gd-DOTA-tetramide 
complexes generally have very slow water exchange kinetics in comparison to Gd-DOTA 
(i.e. the tetraacid complex). This is not ideal for their application as MRI contrast agents. 
However, as indicated above, our aim is to polymerise these monomeric units to generate 
materials that would provide a higher payload of gadolinium per molecule increasing the 
relaxivity this way. This polymeric materials could also see a further enhancement of the 
relaxivity due to the slower tumbling of the resulting molecules, although this effect is 
minimised in systems were the water exchange is slow as is likely to be the case here (in spite 
of this, second coordination sphere interactions can overcome this problem – see for example 
the recent publication by Sherry
48
). The cytotoxicity studies indicate that one of the 
compounds under study (7) is non-toxic at and below 3 mM, while a slight cytotoxicity was 
observed for compound 8 at 3 mM (but not at lower concentrations). We also studied the 
PARACEST properties of europium(III) complex 9 which showed to have an intermediate to 
slow water exchange between the Eu-bound water species and bulk water, as expected.  In 
addition to these studies – directed towards the development of novel MRI contrast agents – 
we also carried out a detailed structural study of one of the ligands (with propargyl 
substituents) and the corresponding Gd
III
, Cd
II
 and Zn
II
 complexes. The single crystal X-ray 
crystallographic studies showed the ligand to be octadentate for the gadolinium and cadmium 
complexes and hexadentate in the case of zinc. This is consistent with the coordination 
chemistry expected in each case.   
 We are currently investigating the formation of hyperbranched polymers from these 
monomers; the resulting species will in turn be loaded with gadolinium(III) to yield new MRI 
contrast agents. These results will be reported in due course.  
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Experimental 
 
Materials and methods. All reactions requiring anhydrous conditions or involving moisture 
sensitive reactants were performed under an atmosphere of dry nitrogen using oven dried 
(80°C) and/or flame dried glassware. Reactants, reagents and special solvents were obtained 
from commercial suppliers and were used without further purification. All common solvents 
were of AnalaR

 grade from BDH and were dried in accordance with established protocols. 
All reaction temperatures reported indicate the temperature of the bath in contact with the 
reaction vessel. The presence of free (i.e. unreacted) gadolinium(III) ions during 
complexation reactions was checked by adding a small volume (approximately 0.2 ml) of 
reaction mixture to a sample tube containing 0.2 ml of a 0.2% aqueous solution of 
methylthymol blue and 2 ml of a pH 6 urotropine buffer (prepared from a 1 M solution of 
urotropine and by dropwise addition of 0.1 M HCl until a pH value of 6 was reached). Flash 
column chromatography was performed using Merck-Kieselgel BDH F254 (230-400 mesh). 
Elemental analyses were performed by the Elemental Analysis Service at London 
Metropolitan University. All 
1
H NMR spectra were recorded as solutions in specified 
deuterated solvents on a Bruker 2 channel DRX-400 spectrometer using the residual protic 
solvent signal as internal reference. 
13
C NMR spectra were recorded on a Bruker 2 channel 
DRX-400 spectrometer as solutions in specified deuterated solvents. FT-IR spectra were 
recorded on a Perkin-Elmer Spectrum RX FT-IR spectrometer with built-in internal 
calibration. The compound to analyse was either pressed together with fine anhydrous 
potassium bromide to obtain a disk, or added as a thin layer between KBr pellets.  Mass 
spectra were recorded under CI
+
 or FAB
+
 conditions on a Micromass AutoSpec Premier 
instrument, or ESI
+
 conditions using a Micromass LCT Premier instrument.  Fluorescence 
emission spectra were obtained using a Horiba Jobin Yvon, Fluorolog-3 spectrofluorimeter, 
using 10 x 10 mm quartz cuvettes.  
 
 
N-allyl-2-chloroacetamide, 1. Chloroacetyl chloride (0.80 ml, 10 mmol) in dry THF 
(2 ml) was cooled down to -10 °C on an ice bath. A solution of dry allylamine (0.75 ml, 10 
mmol) and dry Et3N (1.39 ml, 10.0 mmol) in dry THF (2 ml) was added dropwise over 1 
hour at -10 °C. The mixture was left stirring for 1 h. After removal of the solvent under 
reduced pressure, 0.1 M HCl (15 ml) was added, and the product was extracted with CHCl3. 
The organic phase was dried over anhydrous K2CO3. After evaporation of the solvent under 
reduced pressure, the resulting brown oil was distilled under reduced pressure at 100°C, and 
the pure product was collected as a colourless oil in 67% yield (0.90 g, 6.7 mmol). Elemental 
analysis: calculated C 44.96%, H 6.04%, N 10.49%; found C 45.01%, H 6.11%, N 10.51%. 
CI
+
 MS, m/z: 151 ([M+NH4]
+
), 134 ([M+H]
+
); HSMS: calculated MW 134.0373 a.m.u., 
found 134.0375 a.m.u.). IR (film on KBr pellets), cm
-1
: 3296, 3083, 1664, 1545, 1419, 1324, 
1261, 1240, 1154, 990, 923, 788, 696, 651, 565. 
1
H NMR (400 MHz, 25°C, CDCl3),  (ppm): 
6.71 (br s, 1H, NH), 5.82 (m, 1H, NHCH2CH), 5.18 (m, 2H, NHCH2CHCH2), 4.05 (s, 2H, 
ClCH2CO), 3.92 (m, 2H, NHCH2). 
13
C NMR (100 MHz, 25°C, CDCl3),  (ppm): 165.7 (CO), 
133.2 (NHCH2CH), 116.9 (NHCH2CHCH2), 42.5 (ClCH2), 42.0 (NHCH2). 
 
N-(prop-2-ynyl)-2-chloroacetamide, 2. Chloroacetyl chloride (4.03 ml, 50.6 mmol) 
in dry THF (30 ml) was cooled down to -5 °C on an ice bath. A solution of dry 
propargylamine (3.47 ml, 50.6 mmol) and dry Et3N (7.05 ml, 50.6 mmol) in dry THF (30 ml) 
was added dropwise over 1 hour at -5 °C. The mixture was left stirring for 1 h. After removal 
of the solvent under reduced pressure, 0.1 M HCl (40 ml) was added, and the product was 
extracted with CHCl3 (3x20 ml). The organic phase was dried over anhydrous K2CO3. After 
evaporation of the solvent under reduced pressure, the resulting beige solid was purified by 
flash chromatography (SiO2, EtOAc/c-Hex 50:50 v/v, Rf 0.40), leading to the desired product 
as a white solid in 49% yield (3.27 g, 24.8 mmol). Mp: 68 °C. Elemental analysis: calculated 
C 45.65%, H 4.60%, N 10.65%; found C 45.76%, H 4.68%, N 10.73%. CI
+
 MS, m/z: 149 
([M+NH4]
+
), 132 ([M+H]
+
; calculated 132.0216, found 132.0219), 280 ([2M+NH4]
+
), 263 
([2M+H]
+
). IR (KBr disk), cm
-1
: 3417, 3277, 3057, 2997, 2953, 2122, 1677, 1639, 1618, 
1544, 1447, 1414, 1384, 1318, 1236, 1077, 1004, 931, 783, 696, 659. 
1
H NMR (400 MHz, 25 
°C, CDCl3),  (ppm): 6.77 (br s, 1H, NH), 4.11 (m, 2H, NHCH2), 4.07 (s, 2H, ClCH2CO), 
2.28 (t, 
3
JHH = 2.6 Hz, 1H, C≡CH). 
13
C NMR (100 MHz, 25 °C, CDCl3),  (ppm): 165.6 
(CO), 78.5 (C≡CH), 72.2 (C≡CH), 42.3 (ClCH2), 29.6 (NHCH2). 
 
N-(4-vinylphenyl)-2-chloroacetamide (3). Chloroacetyl chloride (2.00 ml, 25.1 
mmol) in dry THF (15 ml) was cooled down to -5 °C on an ice bath. A solution of 4-
aminostyrene (2.94 ml, 25.1 mmol) and dry Et3N (3.50 ml, 25.1 mmol) in dry THF (15 ml) 
was added dropwise over 1 hour at -5 °C. The mixture was left stirring for 1 h. After removal 
of the solvent under reduced pressure, 0.1 M HCl (30 ml) was added, and the product was 
extracted with chloroform (3x15 ml). The organic phase was dried over anhydrous K2CO3. 
After evaporation of the solvent under reduced pressure, the resulting beige solid was purified 
by flash chromatography (SiO2, EtOAc/c-Hex 40:60 v/v, Rf 0.49), leading to the desired 
product as a white solid in 55% yield (2.70 g, 13.8 mmol). Mp: 138 °C. Elemental analysis: 
calculated C 61.39%, H 5.15%, N 7.16%; found C 61.38%, H 5.07%, N 7.14%. FAB
+
 MS, 
m/z: 196 ([M+H]
+
). IR (KBr disk), cm
-1
: 3474, 3123, 1670, 1615, 1546, 1511, 1403, 1343, 
1297, 1255, 1195, 986, 964, 898, 865, 838, 792, 737, 691. 
1
H NMR (400 MHz, 25 °C, 
CDCl3),  (ppm): 8.24 (br s, 1H, NH), 7.52 (d, 
3
JHH = 8.6 Hz, 2H, H
o
), 7.40 (d, 
3
JHH = 8.6 Hz, 
2H, H
m
), 6.68 (dd, 
3
JHH = 17.6, 
3
JHH = 10.9 Hz, 1H, CH=CH2), 5.71 (d, 
3
JHH = 17.6 Hz, 1H, 
CH=CHH
cis
), 5.23 (d, 
3
JHH = 10.9 Hz, 1H, CH=CHH
trans
), 4.19 (s, 2H, ClCH2). 
13
C NMR 
(100 MHz, 25 °C, CDCl3,),  (ppm): 163.6 (CO), 136.1 (CONHC
ipso
), 135.9 (CH=CH2), 
134.6 (C
p
), 126.9 (C
m
), 120.0 (C
o
), 113.6 (CH=CH2), 42.8 (ClCH2). 
 
1,4,7,10-tetrakis(allylcarbamoylmethyl)-1,4,7,10-tetraazacyclo-dodecane (4). 
Cyclen (0.100 g, 0.581 mmol), K2CO3 (0.401 g, 2.90 mmol) and 1 (0.388 g, 2.90 mmol) were 
suspended in dry MeCN (20 ml) and heated at reflux (85 °C) for 18 h. After removal of the 
solvent under reduced pressure, the residue was suspended in distilled water (20 ml) and the 
product extracted with CHCl3 (5x10 ml). The organic phase was dried over anhydrous K2CO3 
and the solvent was evaporated under reduced pressure. The beige solid residue was purified 
by double precipitation from DCM with cyclohexane, yielding the desired product in 58% 
yield (0.189 g, 0.337 mmol). M.p.: 167 °C. Elemental analysis: calculated C 59.98%, H 
8.63%, N 19.98%; found C 60.02%, H 8.57%, N 19.99%. FAB
+
 MS, m/z: 561 ([M+H]
+
; 
calculated 561.3877, found 561.3871), 583 ([M+Na]
+
). IR (KBr disk), cm
-1
: 3242, 2954, 
2822, 1666, 1541, 1452, 1427, 1368, 1308, 1263, 1227, 1109, 993, 972, 926, 807, 780, 722, 
647, 584, 557. 
1
H NMR (400 MHz, 25 °C, CDCl3),  (ppm): 7.06 (br s, 4H, NH), 5.82 (m, 
4H, NHCH2CH), 5.15 (m, 8H, NHCH2CHCH2), 3.88 (m, 8H, NHCH2), 3.08 (s, 8H, 
NCH2CO), 2.70 (s, 16H, NCH2CH2N). 
13
C NMR (100 MHz, 25 °C, CDCl3),  (ppm): 41.6 
(NHCH2), 53.6 (NCH2CH2N), 59.2 (NCH2CO), 116.4 (NHCH2CHCH2), 134.3 (NHCH2CH), 
170.4 (CO).  
 
1,4,7,10-tetrakis((prop-2-ynyl)carbamoylmethyl)-1,4,7,10-tetraazacyclododecane 
(5). In the course of this investigation, the synthesis of this compound was reported. Our 
synthetic methodology differs slightly from the reported and is therefore reported herein. 
Cyclen (1.66 g, 9.66 mmol), Cs2CO3 (13.85 g, 42.51 mmol) and KI (7.06 g, 42.5 mmol), all 
anhydrous, were suspended in dry DMF (100 ml). Compound 2 (5.59 g, 42.51 mmol) was 
added, and the suspension was stirred at 50 °C for 2 days. After removing the solvent under 
reduced pressure, the brown coloured solid was suspended in H2O (100 ml) and filtered under 
vacuum. The solid residue was washed with H2O until the filtrate was colourless (80 ml). The 
white solid was purified by recrystallisation from a 95:5 v/v mixture of DMF/H2O, yielding 
3.95 g (7.15 mmol, 74%) of the desired product. Mp (°C): 204. Elemental analysis: calculated 
C 60.85%, H 7.30%, N 20.27%; found C 60.98%, H 7.21%, N 20.19%. ESI MS, m/z: 553 
([M+H]
+
; calculated 553.3251, found 553.3257), 575 ([M+Na]
+
), 277 ([M+2H]
2+
). IR (KBr 
disk), cm
-1
: 3283, 3069, 2948, 2825, 2122, 1657, 1532, 1450, 1424, 1360, 1326, 1300, 1259, 
1224, 1143, 1105, 1081, 1044, 1021, 996, 978, 917, 890, 803, 759, 685, 595, 575, 536, 312. 
1
H NMR (400 MHz, 25 °C DMSO-d6),  (ppm): 8.41 (t, 
3
JHH = 5.5 Hz, 4H, NH), 3.87 (m, 
8H, NHCH2), 3.05 (t, 
3
JHH = 2.4 Hz, 4H, CCH), 3.04 (s, 8H, NCH2CO), 2.61 (s, 16H, 
NCH2CH2N). 
13
C NMR (100 MHz, 25 °C, DMSO-d6),  (ppm): 170.4 (CO), 81.2 (CCH), 
72.8 (CCH), 57.4 (NCH2CO), 53.2 (NCH2CH2N), 27.8 (NHCH2).  
 
1,4,7,10-tetrakis((4-vinylphenyl)carbamoylmethyl)-1,4,7,10-
tetraazacyclododecane (6). Compound 3 (0.931 g, 4.76 mmol) and dry Et3N (0.66 ml, 4.8 
mmol) were dissolved in dry DMF (2 ml). A solution of cyclen (0.200 g, 1.16 mmol) in 
distilled water (4 ml) was added dropwise in 1 hour at 50 °C. After 2 hours, the white solid 
precipitate was filtered and washed with distilled water. After drying under reduced pressure 
and in a freeze dryer, the desired product was obtained in 63% yield (0. 60 g, 0.74 mmol). 
Mp: decomposes. Elemental analysis: calculated C 71.26%, H 6.98%, N 13.85%; found C 
71.27%, H 7.07%, N 13.76%. FAB
+
 MS, m/z: 809 ([M+H]
+
), 831 ([M+Na]
+
), 847 ([M+K]
+
). 
IR (KBr disk), cm
-1
: 3239, 3085, 3039, 2976, 2811, 1901, 1674, 1627, 1605, 1514, 1421, 
1403, 1317, 1250, 1180, 1103, 1068, 991, 955, 902, 839, 717, 495. 
1
H NMR (400 MHz, 25 
°C, DMSO-d6),  (ppm): 9.97 (s, 4H, NH), 7.55 (d, 
3
JHH = 8.6 Hz, 4H, H
o
), 7.33 (d, 
3
JHH = 8.6 
Hz, 4H, H
m
), 6.63 (dd, 
3
JHH = 17.6 Hz, 
3
JHH = 11.0 Hz, 4H, CH=CH2), 5.67 (d, 
3
JHH = 17.6 Hz, 
4H, CH=CHH
cis
), 5.14 (d, 
3
JHH = 11.0 Hz, 4H, CH=CHH
trans
), 3.27 (s, 8H, NCH2CO), 2.87 (s, 
16H, NCH2CH2N). 
13
C NMR (100 MHz, 25 °C, DMSO-d6),  (ppm): 169.5 (CO), 138.4 
(CONHC
ipso
), 136.2 (CH=CH2), 132.1 (C
p
), 126.5 (C
m
), 119.2 (C
o
), 112.7 (CH=CH2), 58.0 
(NCH2CO), 52.7 (NCH2CH2N). 
 
Gd-1,4,7,10-tetrakis(allylcarbamoylmethyl)-1,4,7,10-tetraazacyclododecane (7). 
Compound 4 (0.408 g, 0.727 mmol) was dissolved in 30 ml of distilled water. GdCl3·6H2O 
(0.180 g, 0.485 mmol) was added, and the mixture was heated at 50 °C. After 3 hours the test 
with MTB for the presence of free Gd
III
 ions was negative. The solvent was removed under 
reduced pressure, and the residue was suspended in dry DCM, refluxed for 2 h and filtered, 
yielding 0.327 g of white solid (0.388 mmol, 80% respect to the GdCl3·6H2O). Mp: >270 °C 
(decomposition). Elemental analysis: calculated (C28H48N8O4·GdCl3·H2O) C 39.92%, H 
5.98%, N 13.30%; found C 39.79%, H 6.01%, N 13.36%. FAB
+
 MS, m/z: 716 ([Gd(3-2H)]
+
). 
IR (KBr disk), cm
-1
: 1627, 1485, 1462, 1433, 1412, 1388, 1363, 1324, 1297, 1268, 1243, 
1156, 1083, 996, 972, 952, 918, 882, 831, 796, 721, 666, 566, 486.  
  
Gd-1,4,7,10-tetrakis((prop-2-ynyl)carbamoylmethyl)-1,4,7,10-
tetraazacyclododecane, (8). Compound 5 (0.200 g, 0.362 mmol) was suspended in distilled 
water (30 ml). GdCl3·6H2O (0.090 g, 0.241 mmol) was added, and the mixture was heated at 
50 °C. After 4 hours the test with MTB for the presence of free Gd
III
 ions was negative. The 
solvent was removed under reduced pressure, and the residue was washed in a Soxhlet with 
dry DCM for 2 days, resulting in 0.172 g (0.207 mmol) of a white solid (yield: 86% respect 
to the GdCl3·6H2O). Mp: decomposition. Elemental analysis: calculated 
(C28H40N8O4·GdCl3·H2O) C 40.31%, H 5.07%, N 13.43%; found C 40.41%, H 5.15%, N 
13.34%. ESI(+) MS, m/z: 708.2290 ([Gd(5–2H)]+; calculated 708.2257). IR (KBr disk), cm-1: 
3450, 3227, 3085, 2951, 2865, 2109, 1621, 1567, 1462, 1426, 1358, 1324, 1292, 1276, 1085, 
1029, 976, 931, 832, 723, 689. Crystals of complex 8 suitable for X-ray crystallographic 
analysis were obtained by slow diffusion of acetone into an aqueous solution of the 
gadolinium complex. 
 
Eu-1,4,7,10-tetrakis((prop-2-ynyl)carbamoylmethyl)-1,4,7,10-
tetraazacyclododecane, (9). 1,4,7,10-tetrakis(2-propynylcarbamoylmethyl)-1,4,7,10-
tetraazacyclododecane (0.200 g, 0.36 mmol) was suspended in 30 ml of distilled water. 
EuCl3・6H2O (0.073 g, 0.24 mmol) was added, and the mixture was heated at 50°C for 20 
hours. The free ligand was filtered and washed with 20 ml of distilled water. The filtrate was 
freeze-dried and re-crystallized from ethanol affording 0.157 g (0.207 mmol) of white solid 
(yield: 80% in respect to the EuCl3·6H2O). Elemental analysis: calculated 
(C28H40N8O4·EuCl3·2H2O): %C 39.88, %H 5.51, %N 13.06; found: %C 39.70, %H 5.24, %N 
13.23. ESI(+) MS, m/z: 703 [M(5–2H)]+. 1H NMR (500 MHz, 10%D2O in H2O, 25°C): δ 
24.0 (s, 4H, cyclen ring CH2 axial), -2.9 (s, 4H, ring CH2 equatorial), -4.4 (s, 4H, ring CH2 
equatorial), -8.7 (s, 4H, ring CH2 axial), -9.1 (s, 4H, CH2CON), -12. 4 (s, 4H, CH2CON). The 
protons of alkyne and NHCH2 are expected at ~ 2-3 ppm. These are masked by water peak. 
 
Gd-1,4,7,10-tetrakis((4-vinylphenyl)carbamoylmethyl)-1,4,7,10-
tetraazacyclododecane (10). Compound 6 (0.300 g, 0.371 mmol) was suspended in a 1:1 v/v 
mixture of distilled water and DMF (60 ml). GdCl3·6H2O (0.092 g, 0.25 mmol) was added, 
and the mixture was heated at 50 °C. After 3 hours the test with MTB (see General) for the 
presence of free Gd
III
 ions was negative. The solvent was removed under reduced pressure, 
and the residue was washed in a Soxhlet with dry THF for 2 days, resulting in 0.231 g (0.211 
mmol) of white solid (yield: 86% respect to the GdCl3·6H2O). Mp: decomposition. Elemental 
analysis: calculated (C48H56N8O4·GdCl3·H2O) C 52.86%, H 5.36%, N 10.27%; found C 
52.95%, H 5.48%, N 10.23%. ESI(+) MS, m/z:  1000 [Gd(6-H)Cl]
+
. IR (KBr disk), cm
-1
: 
3416, 2976, 1631, 1553, 1511, 1458, 1426, 1407, 1384, 1364, 1323, 1247, 1081, 991, 963, 
908, 844, 714.  
 
Cd-1,4,7,10-tetrakis((prop-2-ynyl)carbamoylmethyl)-1,4,7,10-
tetraazacyclododecane (11). Compound 5 (200 mg, 0.361 mmol) was suspended in 80% 
methanol and refluxed for 10 minutes. After this time Cd(ClO4)26H2O (152 mg, 0.361 
mmol) in 6 ml of methanol was added drop-wise to the reaction mixture. After an additional 
2h of reflux, the solution was cooled to room temperature and ethanol (30 ml) was added. 
The solution was stirred at RT overnight. The volume was reduced to half under reduced 
pressure and the white powder which precipitated was separated by filtration and then 
recrystallized from water and dried under vacuum. (Yield: 165 mg, 53%), Anal. Calc. for 
[C28H40Cl2CdN8O12]: % C, 38.9; % H, 4.67; %N, 12.97 found %C, 39.01;  %H, 4.62; %N, 
13.04. ESI(+) MS, m/z:  765, [Cd(5)ClO4]
+
; 
1
H-NMR (400 MHz, DMSO-d6, 25 °C),  (ppm): 
2.45 (br, 16H, NCH2CH2N), 3.09 (br, 8H, NCH2CO), 3.11 (m, 4H, CCH), 4.02 (m, 8H, 
NHCH2), 9.17 (t, J
3
HH=5.38 Hz, 4H, NH). 
13
C-NMR (400 MHz, DMSO-d6, 25 °C),  (ppm): 
29.1 (NHCH2), 55.3 (NCH2CH2N), 74.4 (CCH), 80.2 (CCH), 172.1 (CO). Crystals of 
complex 11 suitable for X-ray crystallographic analysis were obtained from re-crystallization 
as stated above. 
 
 Zn-1,4,7,10-tetrakis((prop-2-ynyl)carbamoylmethyl)-1,4,7,10-
tetraazacyclododecane (12). Compound 5 (0.500 g, 0.905 mmol) was suspended in 80% 
MeOH (50 ml), and the suspension was heated to reflux (80 °C). A solution of 
Zn(ClO4)2·6H2O (0.337 g, 0.905 mmol) in MeOH (10 ml) was added dropwise, and the 
mixture was refluxed for further 2 hours. After removal of the solvents under reduced 
pressure, a white solid was obtained, that was suspended in distilled H2O and heated to 50 °C 
for 1 hour. The suspension was cooled down to room temperature and filtered. The filtrate 
was dried and purified by precipitation from MeOH with Et2O, leading to a white solid in 
87% yield (0.643 g, 0.787 mmol). Elemental analysis: calculated C 41.17%, H 4.94%, N 
13.72%; found C 41.28%, H 4.91%, N 13.62%. ESI(+) MS, m/z: 308 ([Zn(4)]
2+
), 615 
([Zn(4–H)]+; calculated 615.2386, found 615.2397), 715 ([Zn(4)ClO4]
+
). IR (KBr disk), cm
-1
: 
3411, 3270, 3079, 2930, 2123, 2025, 1631, 1560, 1463, 1431, 1384, 1365, 1311, 1247, 1145, 
1117, 1086, 998, 973, 926. 
1
H NMR (400 MHz, 25 °C, D2O),  (ppm): 4.00 (d, 
3
JHH = 2.4 
Hz, 8H, NHCH2), 3.43 (br s, 4H, NCH2CO), 2.95 (br m, 8H, NCH2CH2N), 2.70 (br m, 8H, 
NCH2CH2N), 2.56 (t, 
3
JHH = 2.4 Hz, 4H, CCH). 
13
C NMR (100 MHz, 25 °C, D2O),  (ppm): 
171.7 (C=O), 79.2 (CCH), 72.2 (CCH), 55.6 (NCH2CO), 50.3 (NCH2CH2N), 29.0 
(NHCH2). Crystals of complex 12 suitable for X-ray crystallography were obtained by slow 
diffusion of acetone into an aqueous solution of the compound. 
 
X-ray crystallography. Crystal data for 5: C28H40N8O4, M = 552.68, monoclinic, P21/c 
(no. 14), a = 9.3718(2), b = 8.1181(2), c = 19.6489(6) Å, β = 101.157(3)°, V = 1466.66(7) Å3, 
Z = 2 [Ci symmetry], Dc = 1.251 g cm
–3, μ(Mo-Kα) = 0.086 mm–1, T = 173 K, colourless 
blocks, Oxford Diffraction Xcalibur 3 diffractometer; 4946 independent measured reflections 
(Rint = 0.0479), F
2
 refinement, R1(obs) = 0.0400, wR2(all) = 0.0927, 2906 independent 
observed absorption-corrected reflections [|Fo| > 4σ(|Fo|), 2θmax = 65°], 189 parameters. 
CCDC 756369. 
 
Crystal data for 8: [C28H42GdN8O5](Cl)3·4H2O·C3H6O, M = 964.44, triclinic,  (no. 2), 
a = 11.1042(3), b = 13.8935(4), c = 15.2301(4) Å, α = 111.233(2), β = 102.814(2), γ = 
100.096(2)°, V = 2049.39(11) Å
3
, Z = 2, Dc = 1.563 g cm
–3, μ(Cu-Kα) = 12.781 mm–1, T = 
173 K, colourless plates, Oxford Diffraction Xcalibur PX Ultra diffractometer; 7848 
independent measured reflections (Rint = 0.0476), F
2
 refinement, R1(obs) = 0.0473, wR2(all) = 
0.1341, 6887 independent observed absorption-corrected reflections [|Fo| > 4σ(|Fo|), 2θmax = 
143°], 480 parameters. CCDC 756370. 
 Crystal data for 10: [C28H40CdN8O4](ClO4)2·H2O, M = 882.00, orthorhombic, Pbcn (no. 
60), a = 20.47188(8), b = 8.61724(3), c = 20.27469(8) Å, V = 3576.68(2) Å
3
, Z = 4 [C2 
symmetry], Dc = 1.638 g cm
–3, μ(Cu-Kα) = 6.918 mm–1, T = 173 K, colourless blocks, 
Oxford Diffraction Xcalibur PX Ultra diffractometer; 3476 independent measured reflections 
(Rint = 0.0283), F
2
 refinement, R1(obs) = 0.0251, wR2(all) = 0.0745, 3263 independent 
observed absorption-corrected reflections [|Fo| > 4σ(|Fo|), 2θmax = 143°], 245 parameters. 
CCDC 756371. 
 
Crystal data for 11: [C28H40N8O4Zn](ClO4)2·H2O, M = 834.97, orthorhombic, Pbcn (no. 
60), a = 21.0162(3), b = 9.01749(12), c = 18.5277(2) Å, V = 3511.25(8) Å
3
, Z = 4 [C2 
symmetry], Dc = 1.579 g cm
–3, μ(Mo-Kα) = 0.928 mm–1, T = 173 K, colourless blocks, 
Oxford Diffraction Xcalibur 3 diffractometer; 5990 independent measured reflections (Rint = 
0.0472), F
2
 refinement, R1(obs) = 0.0466, wR2(all) = 0.1313, 3840 independent observed 
absorption-corrected reflections [|Fo| > 4σ(|Fo|), 2θmax = 65°], 317 parameters. CCDC 756372. 
 
Magnetic resonance studies. Relaxation rate measurements were carried out using a 
2.35 T horizontal magnet with a 120 mm bore (Oxford Instruments Eynsham, UK), interfaced 
to a Surrey Medical Imaging Systems (SMIS, UK) console. The samples were also scanned at 
a higher magnetic field using a 9.4 T horizontal 20 cm bore Varian VNMRS system. 
Reference samples for MRI scanning were made from commercially available DOTAREM
®
 
(Gadoterate meglumine) injection by Guerbet. At 2.35T, T1 was measured at 25 °C using a 
spin-echo pulse sequence with an echo-time TE of 28 ms and an array of repetition-times TR 
of 100, 110, 130, 150, 180, 200, 250, 300, 400, 500, 600, 700, 800, 1000, 1200, 1500, 1800 
and 2500 ms, FOV 100x40 mm, slice thickness 2 mm, resolution 128x64 voxels, 1 averages 
(1 scan/voxel). 300 l solutions of each contrast agent in a 0.1-2.5 mM concentration range in 
double distilled water were prepared and scanned. T2 was measured at 21 °C using a 
saturation recovery sequence with a fixed TR of 1000 ms and an array of TE of 28, 30, 40, 50, 
60, 80 and 100 ms, FOV 30x30 mm, slice thickness 2 mm, resolution 128x64 voxels, 1 
averages (1 scan/voxel). Data Analysis was performed using a Matlab programme (J. Wells, 
ICH, UCL) to calculate T1 and T2 values by selecting a ROI on the MR image and analysing 
the mean pixel intensity values within that ROI at different TRs and fixed TE (for T1) and at 
different TEs and fixed TR (for T2).  
At 9.4T, T1 was calculated using an inversion recovery sequence with the following 
parameters: TE = 30 ms, TR = 17500 ms, IR array = 15; 30; 60; 100; 150; 200; 300; 450; 600; 
900; 1500; 3000; 6000; 17000 ms, FOV 100x40 mm, slice thickness 2 mm, resolution 64x64 
voxels, 1 averages (1 scan/voxel). Acquisition time = 4 h 20 min. T2 weighted images were 
acquired using a spin-echo sequence with fixed TR = 2000 ms, TE array = 20; 30; 40; 50; 60; 
90; 120; 180; 250 ms, FOV 100x40 mm, slice thickness 2 mm, resolution 64x64 voxels, 1 
averages (1 scan/voxel). Acquisition time = 20 min. Data Analysis was performed on ImageJ 
by processing the T1 and T2 maps obtained by the 9.4 T software. T1 and T2 values were 
calculated from the intensity of the pixels in the ROIs we selected on the T1 and T2 maps.  
 
CEST NMR experiment. CEST measurements were carried out by following a 
previously reported procedure.
49
 The sample for CEST study was prepared by dissolving the 
appropriate amount of complex 9 in H2O:D2O 9:1 to yield a 20 mM solution. NMR spectra 
were recorded on a Bruker Avance NMR spectrometer equipped with a narrow-bore 9.4 T 
superconducting magnet. 1D 
1
H NMR measurements were carried out without water 
suppression. Complex data points (128 k) were acquired with a dwell time of 12.4 µs. Prior to 
Fourier transform, the data were apodized with an exponential filter (line broadening = 5 Hz). 
All spectra were calibrated relative to the H2O frequency. CEST spectra were recorded using 
standard continuous-wave irradiation (2 s pulse duration; 22.1 µT pulse amplitude). This was 
done to selectively presaturate the exchangeable-proton resonances. 160 individual 1D 
1
H 
NMR spectra were acquired at different values of the pre-saturation offset frequency (500 Hz 
intervals from 40 kHz to -40 kHz). The data were stored in a single 2D NMR data set and re-
constructed as CEST spectrum by integrating the water signal of each individual spectrum in 
the 2D data set and plotting it as a function of the pre-saturation offset frequency. 
 
 
Incubation for cell viability tests. ST14A cells were cultured on adherent flasks 
(TPP) in DMEM (Dulbecco’s modified Eagle medium, Invitrogen) with 10% foetal calf 
serum (Gibco) and 1% Penicillin-Streptomycin. Cells were incubated at 33
o
C with 5% CO2 
and 100% humidity. Cells were passaged every 48 hours, using 1X Trypsin-EDTA to detach 
cells from adherent flasks, collected and centrifuged in 10ml culture medium, replated 1:3 in 
fresh culture medium, and returned to the incubator. The ST14A cell line was established by 
immortalisation of foetal striatal cells from developmental stage E14 through retroviral 
transduction of the SV40 Large T Antigen oncogene.
45
 The cells proliferate at 33
o
C, and 
proliferation is inactivated at 39
o
C. Cells were incubated in solutions containing different 
concentrations of the corresponding complex (0-10mM) for 24 hours, then contrast agents 
were removed and cells washed in EBSS prior to cell viability testing. 
 
 
Alamar Blue assay.
46
 Alamar Blue is a non-toxic oxidation-reduction (redox) 
indicator dye for the quantification cell metabolism and growth. Reduction of NADH occurs 
during cell metabolism and growth, and the Alamar Blue dye changes colour in a reduced 
environment. After washing with EBSS (Earl’s balanced salt solution, Invitrogen), cells were 
seeded into the wells of a 96-well plate (100 l/well) with culture medium containing 10% 
w/v Alamar Blue, 10% w/v FCS and 1% penicillin-streptomycin in DMEM. Cells were 
plated at a density of 10
4
 cells per well, and 8 wells per treatment group. Incubation was 
carried out at standard conditions of 5% CO2 in air, 33°C and 100% humidity. As negative 
control, wells with Alamar Blue solution were also prepared with no cells and with cells 
previously incubated without a contrast agent. After 24 hours, 3 absorbance values for each 
dish were measured at 570 nm with an ELISA plate reader (Revelation). 
 
Methylene Blue assay.
47
 Cells were washed with EBSS and fixed onto a 96-well 
plate. 100 l of 1% w/v Methylene Blue in 0.01 M borate buffer (pH 8.4) was added to each 
well. After 30 minutes the plates were washed with borate buffer and dried at room 
temperature. The dye was solubilised adding 100 l of 0.1 M HCl to each well, and the 
absorbance at 650 nm was measured for each well with an ELISA plate reader. 
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Text and Figure for Table of Contents 
 
Three gadolinium(III) complexes with tetraazamacrocyclic ligands containing four amide 
substituents that feature groups suitable for polymerisation have been synthesised. The 
relaxation enhancement properties and cytotoxicity of two of these complexes have been 
determined. The X-ray crystal structures of one of the ligands and its corresponding 
gadolinium(III), zinc(II) and cadmium(II) complexes have been determined (the one with 
gadolinium(III) is pictured below). 
 
 
